FGFR2 FGFR2-TACC3

在晚期癌症的临床测序项目中，Wu等人已经确定了许多不同癌症类型患者的FGFR融合。这些融合也被发现保持寡聚能力，并导致细胞增殖增强。这些融合被证明对帕佐帕尼布有反应。作者利用这些病例强调需要加强临床测序工作。
In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.